Drug Profile
Mesalazine rectal 1g suppositories (MAX 002) - Aptalis Pharma
Alternative Names: 5-ASA 1g rectal suppositories - Aptalis Pharma; MAX 002; MAX-002 1g suppositories - Aptalis Pharma; Mesalamine 1g rectal suppositories - Aptalis Pharma; Mesalazine rectal high-concentration - Aptalis PharmaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Axcan Pharma
- Developer Aptalis
- Class Aminosalicylic acids; Anti-inflammatories; Antineoplastics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ulcerative proctitis
Most Recent Events
- 07 May 2014 No development reported - Phase-III for Ulcerative proctitis in Canada (Rectal)
- 07 May 2014 No development reported - Phase-III for Ulcerative proctitis in Poland (Rectal)
- 07 May 2014 No development reported - Phase-III for Ulcerative proctitis in USA (Rectal)